Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

232

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

232 results for “RNA therapeutics”

Learn how ShareScore rates datasets ↗
zenodo44/100

Data files: Single-cell RNA profiling of Plasmodium vivax-infected hepatocytes reveals parasite- and host- specific transcriptomic signatures and therapeutic targets

<p>Scripts, preprocessed count matrices, and single-cell data objects generated&nbsp;in&nbsp;<strong>&ldquo;Single-cell RNA profiling of&nbsp;<em>Plasmodium vivax</em><em>-</em>infected hepatocytes reveals parasite- and host- specific transcriptomic signatures&nbsp;and therapeutic targets&rdquo;&nbsp;</strong></p>

opencc-by-4.0Jul 2022View details →
zenodo40/100

Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq

<p><strong><a href="https://gitlab.com/bu_cnio/Beyondcell">Beyondcell</a>&nbsp;</strong>is a methodology for the identification of drug vulnerabilities in single cell RNA-seq data. To this end, <strong>Beyondcell</strong> focuses on the analysis of drug-related commonalities between cells by classifying them into distinct therapeutic clusters. We have validated the tool in a population of MCF7-AA cells exposed to 500nM of bortezomib and collected at different time points: t0 (before treatment), t12, t48 and t96 (72h treatment followed by drug wash and 24h of recovery) obtained from <a href="https://www.nature.com/articles/s41586-018-0409-3"><strong><em>Ben-David U, et al., Nature, 2018</em></strong></a>. Here, you can find the integrated Seurat object obtained from this analysis. This object is meant to help users follow <strong>Beyondcell&#39;s</strong>&nbsp;<a href="https://gitlab.com/bu_cnio/Beyondcell/-/tree/master/tutorial/analysis_workflow">analysis workflow</a>.</p> <p>&nbsp;</p>

opencc-by-4.0Jan 2021View details →
zenodo36/100

Single-cell RNA-Seq-based deconvolution of hairy cell leukemia reveals novel disease drivers and identifies DUSP1 as potential therapeutic target

<p>Microwell-based (BD Rhapsody) scRNA-seq of Hairy Cell Leukemia Patients published in&nbsp;</p> <blockquote> <p><strong>Single-cell RNA-Seq-based deconvolution of hairy cell leukemia reveals novel disease drivers and identifies DUSP1 as potential therapeutic target, Jan-Paul Bohn et al. Submitted.</strong></p> </blockquote> <p>The files will be made available upon publication.&nbsp;<br></p> <h4><strong>Description of the files</strong></h4> <ul> <li><strong>01_raw_counts: </strong>count matrices as CSV as generated by the BD Rhapsody WTA analysis pipeline</li> <li><strong>10_prepare_adata</strong>: Load BD Rhapsody WTA analysis pipeline outputs into AnnData objects and add metadata.</li> <li><strong>20_scrnaseq_qc</strong>: Use a nextflow pipeline (stored in lib/single-cell-analysis-nf) to perform threshold-based filtering of single-cell data and apply SOLO for doublet detection.</li> <li><strong>30_merge_adata</strong>: Merge samples into a single AnnData object, train a scVI model for batch effect removal, and annotate cell-types based on unsupervised clustering</li> <li><strong>40_cluster_analysis</strong>: Identify and investigate subclusters representing cell-states that go beyond the major cell-types</li> <li><strong>50_de_analysis</strong>: Generate pseudobulk and perform differential gene expression analysis using DESeq2 (based on a wrapper script stored in lib/deseq2_workflow)</li> <li><strong>70_downstream_analysis</strong>: Perform pathway analyses and generate figures for publication based on the data generated in the previous steps</li> <li><strong>containers:</strong> Conda environments used for the analysis packed up as singularity containers.&nbsp;</li> </ul>

opencc-by-4.0Dec 2023View details →
zenodo36/100

Dataset related to: Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy

<p>The files contain all the dataset included in the manuscript divided by figures.</p> <p>&nbsp;</p> <p>Abstract</p> <p>Alternative pathway complement dysregulation with abnormal glomerular C3 deposits and glomerular damage is a key mechanism of pathology in C3 glomerulopathy (C3G). No disease-specific treatments are currently available for C3G. Therapeutics inhibiting complement are emerging as a potential strategy for the treatment of C3G. In this study, we investigated the effects of N-acetylgalactosamine (GalNAc) conjugated small interfering RNA (siRNA) targeting the C3 component of complement that inhibits liver C3 expression in the C3G model of mice with heterozygous deficiency of factor H (Cfh+/- mice). We showed a duration of action for GalNAc-conjugated C3 siRNA in reducing the liver C3 gene expression in Cfh+/- mice that were dosed s.c. once a month for up to 7 mo. C3 siRNA limited fluid-phase alternative pathway activation, reducing circulating C3 fragmentation and activation of factor B. Treatment with GalNAc-conjugated C3 siRNA reduced glomerular C3d deposits in Cfh+/- mice to levels similar to those of wild-type mice. Ultrastructural analysis further revealed the efficacy of the C3 siRNA in slowing the formation of mesangial and subendothelial electron-dense deposits. The present data indicate that RNA interference mediated C3 silencing in the liver may be a relevant therapeutic strategy for treating patients with C3G associated with the haploinsufficiency of complement factor H.</p>

opencc-by-4.0Mar 2022View details →
ClinicalTrials.gov32/100

Study to Investigate the Therapeutic Role of RNA Fragments in Platelet Production During Chemotherapy

ClinicalTrials.gov study NCT01163110. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
geo24/100

A plastic EMP1⁺ to LGR5⁺ cell state conversion as a therapeutic bypass to KRAS-G12D inhibition in metastatic colorectal cancer [RNA-Seq]

GEO Series GSE303692. Mus musculus. 24 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenSep 2025View details →
geo24/100

Discovery, delineation and therapeutic targeting of a hyper-translation pathway driving cytokine release syndrome [RSK1_KO_RNA-seq]

GEO Series GSE287445. Mus musculus. 4 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenDec 2025View details →
geo24/100

CXCL8/CXCR2 signaling is Enriched in Fibrotic Myeloproliferative Neoplasms and is Vulnerable to Therapeutic Inhibition [RNA-Seq]

GEO Series GSE189979. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenMay 2023View details →
geo24/100

Recurrent FGFR-alterations are frequent oncogenic drivers and therapeutic targets in pediatric low-grade gliomas [RNA-Seq 2]

GEO Series GSE286565. Homo sapiens. 40 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenMay 2025View details →
geo24/100

Alveolar Soft Part Sarcoma is driven by ASPSCR1::TFE3-dependent and therapeutically targetable transcriptional programs [RNA-Seq]

GEO Series GSE235738. Homo sapiens. 35 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenApr 2024View details →
geo24/100

Whole-genome CRISPR screening identifies N-glycosylation as an essential pathway and a potential novel therapeutic target in CALR-mutant MPN (RNA-Seq).

GEO Series GSE203457. Mus musculus. 16 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenSep 2022View details →
geo24/100

Targeting the lineage-specific long non-coding RNA LINC01212 as an effective anti-melanoma therapeutic strategy [2]

GEO Series GSE70177. Homo sapiens. 9 samples. Type: Expression profiling by array.

openGEO-OpenJan 2016View details →
geo24/100

RNA decay defines the therapeutic response to transcriptional perturbation in leukemia [SLAMseq THP1 RNAPII targeting]

GEO Series GSE229312. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenApr 2023View details →
geo24/100

ARID1A is a critical regulator of luminal identity and therapeutic response in oestrogen receptor-positive breast cancer (RNA-Seq)

GEO Series GSE124227. Homo sapiens. 10 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenNov 2019View details →
geo24/100

Integrated analysis of MLL-AF9 AML patients and model leukemias highlights RET and other novel therapeutic targets (RNA-seq shRNA)

GEO Series GSE72041. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenMar 2017View details →
geo24/100

Transcriptomic Characterization Reveals Disrupted Medium Spiny Neuron Trajectories in Huntington's Disease and Possible Therapeutic Avenues [Bulk RNA-seq treated with Cerulenin]

GEO Series GSE232647. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJul 2025View details →
geo24/100

Identification of PRMT5 as a therapeutic target in cholangiocarcinoma [RNA-seq II]

GEO Series GSE270181. Mus musculus. 9 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJun 2025View details →
geo24/100

RNA N6-methyladenosine methyltransferase METTL3 drives NAFLD-HCC and is a therapeutic target for boosting immunotherapy [RNA-Seq]

GEO Series GSE233806. Homo sapiens. 4 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenAug 2023View details →
geo24/100

Chemical Inhibition of Salt-Inducible Kinase as Therapeutic Strategy in Acute Myeloid Leukemia [RNA-Seq]

GEO Series GSE129862. Mus musculus; Homo sapiens. 14 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenNov 2019View details →
geo24/100

Enhancing Non-Small Cell Lung Cancer Treatment Utilizing Natural Killer Cell-Derived Extracellular Vesicles (NKEVS) As A Novel Adoptive Cellular Therapeutic [EV RNA]

GEO Series GSE274584. Homo sapiens. 21 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJul 2025View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record